20 December 2012 | News | By BioSpectrum Bureau
Singapore: Sanofi US entered into a settlement agreement with the US Attorney's Office, District of Massachusetts, US Department of Justice and multiple states and resolved all claims arising out of an investigation into sampling of Sanofi's former visco supplement product, Hyalgan.
As part of the settlement, Sanofi US will pay $109 million to the settling parties and is also expected to enter into a corporate integrity agreement with the office of the inspector general of the US Department of Health and Human Services. Criminal charges have not been filed against the company in connection with this matter.
Before the government initiated the investigation that led to this settlement, Sanofi identified concerns with Hyalgan sampling through the operation of its compliance program and immediately took strong, proactive and effective steps to address these issues and voluntarily stopped sampling Hyalgan in 2009. The matter has been resolved within existing financial reserves.
Sanofi co-operated fully with the US government's review of the matter and said that it was pleased to have reached a resolution. Sanofi highlighted that it is committed to conducting business with the highest standards of integrity and takes very seriously its obligation to do so.